CrossMark

Organ-specific alteration in caspase expression and STK3 proteolysis during the aging process

Mélissa Lessard-Beaudoin [a,b], Mélissa Laroche [a,b], Amal Loudghi [a,b],
Marie-Josée Demers [a,b], Jean-Bernard Denault [b,c,d], Guillaume Grenier [c,e],
Sean-Patrick Riechers [f], Erich E. Wanker [f], Rona K. Graham [a,b,*]

[a] Research Centre on Aging, University of Sherbrooke, Sherbrooke, Faculty of Medicine and Health Sciences, Quebec, Canada
[b] Department of Pharmacology and Physiology, University of Sherbrooke, Sherbrooke, Faculty of Medicine and Health Sciences, Quebec, Canada
[c] CHUS Research Center, University of Sherbrooke, Sherbrooke, Faculty of Medicine and Health Sciences, Quebec, Canada
[d] Institut de Pharmacologie de Sherbrooke, University of Sherbrooke, Sherbrooke, Faculty of Medicine and Health Sciences, Quebec, Canada
[e] Department of Orthopaedic Surgery, University of Sherbrooke, Sherbrooke, Faculty of Medicine and Health Sciences, Quebec, Canada
[f] Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany

ARTICLE INFO

ABSTRACT

Caspases and their substrates are key mediators of apoptosis and strongly implicated in various physiological processes. As the serine/threonine kinase family is involved in apoptosis and serine/threonine kinase 3 (STK3) is a recently identified caspase-6 substrate, we assessed the expression and cleavage of STK3 in murine peripheral organs and brain regions during the aging process. We also assessed caspase-3, -6, -7, and -8 expression and activity in order to delineate potential mechanism(s) underlying the generation of the STK3 fragments observed and their relation to the apoptotic pathway. We demonstrate for the first time the cleavage of STK3 by caspase-7 and show that STK3 protein levels globally increase throughout the organism with age. In contrast, caspase-3, -6, -7, and -8 expression and activity vary significantly among the different organs analyzed suggesting differential effects of aging on the apoptotic mechanism and/or nonapoptotic functions of caspases throughout the organism. These results further our understanding of the role of caspases and their substrates in the normal aging process and highlight a potential role for STK3 in neurodegeneration.

© 2016 Elsevier Inc. All rights reserved.

1. Introduction

Caspases are cysteinyl peptidases that are activated by proteolysis and dimerization. This leads to cleavage of their substrates and ultimately cell death through the programmed cell death pathway. The caspase family is essential not only for cell death but also for immunity, neurogenesis, synaptic activity, and cell proliferation and differentiation (D'Amelio et al., 2010; Kuranaga and Miura, 2007; Schwerk and Schulze-Osthoff, 2003). Activation of caspases is observed in many physiological and pathological processes including Alzheimer's disease, Huntington's disease, stroke, and aging (Broughton et al., 2009; Graham et al., 2011; LeBlanc, 2013; Lee and Kim, 2006; Pattison et al., 2006; Snigdha et al., 2012). The expression levels and activity of caspases during the aging process are organ and tissue specific. For instance, in the cerebral

cortex of Wistar rats, caspase-3 (CASP3) protein expression decreases with aging whereas caspase-8 (CASP8) increases from 12 months of age onward (Shimohama et al., 2001). In contrast to the cortex, CASP3 expression levels do not change in the skeletal muscle of aged-Fischer 344/Brown Norway rats compared to their younger counterparts (Chung and Ng, 2006).

The serine/threonine kinase 3 (STK3), also known as STE-20-like kinase MST2 (MST2), is a 56-kDa protein in the germinal center kinase group II of the mitogen-activated protein kinase family and is involved in apoptosis, differentiation, and proliferative signaling (Heallen et al., 2011; Kim et al., 2010; Li et al., 2013; Liu et al., 2012b; Oh et al., 2009; Qin et al., 2013). This pathway is often referred to as the signaling pathway of its ortholog in Drosophila melanogaster, the Hippo signaling pathway. The activation of STK3 leads to the phosphorylation of Mps One kinase activator-like 1, large tumor suppressor 1 and 2 and yes-associated protein. This results in the cytoplasmic retention and degradation of yes-associated protein inhibiting the latter from promoting the transcription of proliferative genes such as c-myc and cyclin E via the transcription factor Scalloped/TEAD. STK3 also mediates the phosphorylation of the Forkhead box O (FOXO) transcription

* Corresponding author at: Department Pharmacology and Physiology, Faculty of Medicine and Health Sciences, University of Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada. Tel.: 819-346-1110 x16813; fax: 819-564-5399.
E-mail address: Rona.Graham@USherbrooke.ca (R.K. Graham).

factor family leading to the transcription of proapoptotic genes such as FasL, TRAIL, and PUMA (Liu et al., 2012a) (Fig. 1).

The 2 main post-translational modifications known to regulate STK3 activity are phosphorylation and caspase-mediated cleavage. STK3 can homodimerize or heterodimerize with its homolog STK4 (MST1) allowing its activation by autophosphorylation whereas the protein phosphatase 1 and 2A inactivate it (Deng et al., 2003). STK3 is also regulated by CASP3 cleavage, which results in the production of 34-kDa N-terminal fragments (Deng et al., 2003; Lee et al., 1998). These fragments are resistant to dephosphorylation by protein phosphatases (Deng et al., 2003) and conserve kinase activity. We have recently shown that STK3 is a caspase-6 (CASP6) substrate (Riechers et al., 2016), and a multiple sequence alignment of STK3 demonstrates that the caspase-cleavage sites V63EID and D319ELD are conserved down to *Caenorhabditis elegans* and *Anopheles gambiae*, respectively, suggesting important roles for the fragments generated. The caspase substrate STK4 is cleaved by CASP3, 6, and 7 (O'Neill et al., 2005).

The majority of the work on STK3 has been made during development. However, the increase of caspase activity and production of reactive oxygen species in neurodegenerative diseases and during aging suggest that the production of STK3 fragments may play a role in neurodegeneration (Graham et al., 2011; Merksamer et al., 2013; Patten et al., 2010; Zhang et al., 2003). We have previously shown that in striatal cells expressing mutant huntingtin the level of STK3 and its fragments are increased compared to controls (Riechers et al., 2016).

In order to gain a better understanding of apoptotic mechanisms and the role of STK3 in aging throughout the organism, we characterized the messenger RNA (mRNA) and protein expression of STK3 in the normal aging process in peripheral organs and brain regions of C57BL/6 male mice. Moreover, we assessed the expression and activity levels of CASP3, 6, 7, and 8 in order to further our understanding of the potential mechanism(s) underlying the in vivo generation of STK3 fragments and their relation to the programmed cell death pathway.


Fig. 1. STK3 pathway. In the presence of oxidative stress, Grx1 and Trx1 dissociates from STK3 promoting its activation by autophosphorylation. STK3 is also activated indirectly by the EGFR via PI3K/Akt signaling. The phosphorylation cascade is promoted by STK3 activation that results in a downregulation of proproliferative genes via the degradation of YAP. The cascade also upregulates the proapoptotic genes by the phosphorylation of YAP and the phosphorylation of FOXO transcription factor. STK3 activity is decreased by the phosphatases (PP1 and PP2A) and Raf-1 and it is increased by RASSF1A, c-abl, and its cleavage by caspase-3, which produces a constitutively active fragment that is resistant to dephosphorylation. Abbreviations: EGFR, epidermal growth factor; Grx1, glutaredoxine; PI3K/Akt, phosphoinositide 3-kinase/protéine kinase B; STK3, serine/threonine kinase 3; Trx1, thioredoxine; YAP, Yes-associated protein.

2. Material and methods

2.1. Animals

Peripheral organs and brain regions were collected as described previously from C57BL/6 male mice and grouped according to age: 3–4 months, 12 months, 23–28 months, and older than 30 months (Lessard-Beaudoin et al., 2015). The animal care and ethics committee of University of Sherbrooke approved the protocols for this study (protocols 303–12 and 133–14B). The mice were anesthetized (isoflurane, Abbott) and euthanized by cervical dislocation. The upper part of the cranium was removed, and the brain was collected. The cortex, cerebellum, striata, and hippocampi were then dissected. In parallel, kidney, liver, heart, and spleen were harvested.

2.2. Western blot analyses

Peripheral organs and brain regions were homogenized and sonicated in lysis buffer (0.32-mM sucrose, 20-mM Tris pH 7.2, 1-mM MgCl$_2$, 0.5-mM EDTA pH 7.2) using a cocktail of protease inhibitors (Roche), 4.2-mM Pefabloc SC (Roche), and 10-μM Z-VAD-fmk (Enzo Life Sciences) and clarified by centrifugation at 13,000 rpm. The protein concentration was determined using the bicinchoninic acid protein assay kit (Pierce). Protein lysates (50 μg) were separated on a 7.5% or 10% sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) gel and transferred to a polyvinylidene difluoride membrane (PerkinElmer). The membranes were probed with anti-STK3 (ab52641, Abcam, 1:1000), anti-CASP3 (9662, Cell signaling, 1:1000), anti-CASP6 (9762, Cell signaling, 1:500), anti-CASP7 (9492, Cell signaling, 1:1000), anti-CASP8 (9746, Cell signaling, 1:1000), or anti-actin (MAB1501, Millipore, 1:10,000) antibodies. Peroxidase activity was detected, and densitometric values were obtained with the Odyssey Fc imaging system (Mandel) using Luminata Crescendo Western horseradish peroxidase substrate (Millipore). Quantification of β-actin or Coomassie staining was used to standardize the amount of protein in each lane depending on the protein stability in each organ and densitometric values obtained with the Odyssey Fc imaging system (Mandel).

2.3. Real-time quantitative reverse transcription–polymerase chain reaction

Total RNA was extracted from peripheral organs and brain regions with the RNeasy Mini Kit (Qiagen), and complementary DNAs were prepared using ProtoScript Reverse Transcriptase II (#M0368X, New England BioLabs). Quantification was done using Mx3005P QPCR Systems (Stratagene) with mouse-specific β-actin primers (forward 5′-ACGGCCAGGTCATCACTATTG-3′; reverse 5′-CAAGAAGGAAGGCTGGAAAAGA-3′), STK3 primers (forward 5′-AGGCCCTATGTCCAACAGTG-3′ and reverse 5′-CCATCATGGGGTCTAGTGCT-3′), CASP3 Primers (forward 5′-TGTCATCTCGCTCTGGTACG-3′ and reverse 5′-TCCCATAAATGACCCCTTCA-3′), CASP6 primers (forward 5′-TGGCTCCTGGTACATTCAGGAT-3′ and reverse 5′-TCCGTGAACTCCAGGGAACT-3′), and CASP8 primers (forward 5′-CCTAGACTGCAACCGAGAGG-3′ and reverse 5′-GCAGGCTCAAGTCATCTTCC-3′). Amplification of β-actin was used to standardize the amount of sample RNA in the reaction. Gene-expression levels were measured using MxPro QPCR Software (Stratagene).

2.4. Caspases cleavage assays

Recombinant caspases were expressed, purified, and characterized as described elsewhere (Boucher et al., 2014). Caspases were diluted in a reaction buffer (100-mM Hepes pH 7.4, 200-mM NaCl, 0.2% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 2-mM EDTA, 20% glycerol) at a concentration of 2000 nM and serially diluted. Final concentrations used for each caspase in the assay were 0, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, and 1000 nM. The diluted recombinant caspases and 50 μg of brain lysate were preheated separately at 37 °C for 30 minutes, then mixed and incubated for 90 minutes at 37 °C. Immunoblotting was performed as described above.

2.5. Caspases activity assays

Murine tissues were homogenized as described above without caspases inhibitors, and the lysates were diluted with reaction buffer (100-mM Hepes pH 7.4, 200-mM NaCl, 0.2% CHAPS, 2 mM EDTA, 20% glycerol and 20% dithiothréitol). The activity of endogenous CASP3, 6, and 8 was measured in the lysates using the preferred fluorogenic substrates Ac-DEVD-7-Amino-4-trifluoromethylcoumarin (AFC), Ac-VEID-AFC, and Ac-IETD-AFC, respectively (Enzo Life sciences) at 37 °C for 60 minutes. It is noted that AcDEVD-AFC is also the preferred substrate of CASP7 and that no small peptidic substrate is specific to a particular caspase (McStay et al., 2008). The fluorescence generated was measured by the VICTOR X Multilabel Plate Reader spectrophotometer (PerkinElmer).

2.6. Statistical analysis

Student *t* test, 1-way analysis of variance (ANOVA), and the post hoc Tukey's multiple comparison tests were used for analysis between the age groups. The statistical significance was established at 0.05 (*$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$). GraphPad Prism 6.0 software was used for all statistical analysis (GraphPad Software, La Jolla, CA, USA).

3. Results

3.1. Differential cleavage of STK3 by CASP3, 6, and 7

As STK4 is differentially cleaved by CASP3, 6, and 7 producing fragments with specific functions, we assessed the cleavage of STK3 by these caspases (Song and Lee, 2008). Murine brain lysate was incubated with active site–titrated recombinant CASP3, 6, or 7, and STK3 cleavage was assessed. As expected, CASP3 and CASP6 cleave STK3 (Lee et al., 2001; Riechers et al., 2016). However, we also observed cleavage by CASP7 and noted that the caspases do not cleave STK3 with the same efficacy and do not produce the same fragment sizes. A higher concentration of CASP6 or 7 is required to cleave STK3 and generate the 34-kDa fragment when compared to CASP3. Interestingly, CASP6 is the only caspase that generates the 39-kDa STK3 fragment (Fig. 2).

3.2. Region-specific alterations in STK3 expression with aging in peripheral organs

As the STK family is involved in multiple physiological processes, we assessed the mRNA and protein expression of STK3 and its fragments during the aging process. In the heart, a significant decrease in STK3 mRNA expression is observed by >30 months. In contrast, while there is a significant decrease in STK3 mRNA in the kidney at 12 months of age, it then increases after 23–28 months (Fig. 3). No significant difference in STK3 mRNA expression is observed with aging in the liver (ANOVA test). However, the mRNA expression decreases significantly (43%) at 23–28 months of age in the liver (*t* test). In contrast to the heart and the kidney, STK3 mRNA expression level increases significantly (47%) in the spleen with aging until 23–28 months of age (Fig. 3).

Fig. 2. STK3 is cleaved by caspase-3, -6, and -7. Brain lysate was incubated with serial dilutions of recombinant caspase-3, -6, or -7 and analyzed by immunoblotting. The concentrations of caspases from lane 1 to 9 are 0, 7.81, 15.63, 31.25, 62.5, 125, 250, 500, and 1000 nM, respectively. STK3 is cleaved by the all the executioner caspases albeit with varying efficacies (caspase-3 > caspase-7 > caspase-6). Abbreviation: STK3, serine/threonine kinase 3.

Fig. 3. STK3 mRNA expression levels in peripheral organs. STK3 mRNA expression levels tend to decrease at 23–28 months of age in the liver (t test: 3 months vs. 23–28 months, $p < 0.05$). In the kidney and the heart, STK3 mRNA decreases with aging (kidney: ANOVA $p = 0.04$, t test: 3 months vs. 12 months, $p < 0.05$; 12 months vs. 23–28 months, $p < 0.001$; heart: ANOVA $p = 0.02$, post hoc: 3 months vs. 30 months, $p < 0.01$; t test: 12 months vs. >30 months, $p < 0.01$). In contrast to the other peripheral organs, an increase of STK3 mRNA expression level is observed with the aging in the spleen (ANOVA $p = 0.009$, post hoc: 3 months vs. 23–28 months, $p < 0.01$; 12 months vs. 23–28 months, $p < 0.05$). n = 5 by age group. Tukey's post hoc are presented on the graphs with a continuous line, and t tests are presented on the graphs with dotted line. $^*p < 0.05$; $^{**}p < 0.01$; $^{***}p < 0.001$. Abbreviations: ANOVA, analysis of variance; mRNA, messenger RNA; STK3, serine/threonine kinase 3.

Overall, no significant change in STK3 protein expression levels is observed in the liver with aging (ANOVA). However, comparing the groups using t test shows that STK3 full-length (FL) protein levels decrease initially from 3 to 12 months of age and then increase at >30 months of age when compared to the 12-month values (Fig. 4A). The STK3 39-kDa fragment expression levels in the liver also decrease at 12 months of age, whereas the 34-kDa STK3 fragment expression increases by 76% at >30 months of age when compared to 3 and 12 months age group (Fig. 4A). In the kidney, a 3-fold increase is observed for the STK3 39-kDa fragment expression after the age of 12 months (Fig. 4B). While no significant variation in STK3 protein expression is observed in the heart, a positive correlation is observed in the STK3 34-kDa fragment with age (Fig. 4C). No significant variation in STK3 FL protein expression level is observed in the spleen; however, a 2- to 3-fold increase is observed in STK3 39-kDa and 34-kDa fragments suggesting that an increase in STK3 cleavage occurs with age in the spleen (Fig. 4D).

3.3. Region-specific variations in STK3 expression in the brain with aging

STK3 mRNA expression increases by 68% at 12 months of age in the cortex then decreases after 23 months of age. Hippocampal-STK3 mRNA expression increases up to 23–28 months of age and then decreases at >30 months of age. In the striatum, the mRNA expression levels of STK3 increase with aging (76%). In the cerebellum, no age-dependent effects are observed (Fig. 5).

In the cortex and the cerebellum, both the STK3 FL and the 34-kDa fragment forms increase significantly during the aging process (Fig. 6A and B). In contrast to other brain regions, no significant variation in the STK3 protein expression is observed in the striatum

with age. However, a positive correlation is observed for the STK3 34-kDa fragment (Fig. 6C).

3.4. Differential expression and activity of caspases in peripheral organs with aging

In the liver, CASP6 and 8 mRNA expression levels decrease at 23–28 months of age. In contrast, an increase in mRNA expression of CASP3 and 6 is observed in the kidney after the age of 12 months. Similar to the liver, mRNA expression level of all caspases analyzed decreases at >30 months of age in the heart. No significant variation in any caspases is observed in the spleen with age (Fig. 7).

With regards to caspase protein expression levels, cleaved (active) CASP3 and CASP6 proform expression decreases and no significant variation in CASP7 protein level is observed in the liver with the aging (Fig. 8A and B). In contrast, an ∼5-fold increase of all protein forms of casp8 is observed in the liver after 3 months of age (Fig. 8D). In the kidney, the CASP3 zymogen (inactive form) significantly increases (54%) with age (Fig. 8E). A global increase in CASP6 and cleaved CASP8 expression levels is also observed in the kidney with aging (Fig. 8F and H). Interestingly, a 65-fold increase is observed in the CASP8-cleaved p43/41 form and a 26-fold increase is observed in cleaved CASP8 fragment in the kidney (Fig. 8H). Of note, and dissimilar to the other caspases, CASP7 expression level tends to decrease with age in the kidney (Fig. 8G). In contrast to the liver and the kidney, no significant variation is observed for CASP3

Fig. 4. Global increase of STK3 protein expression levels in peripheral tissues. (A) The FL form of STK3, and the 34 kDa fragment increase in the liver with age (FL: *t* test: 3 months vs. 12 months, *p* < 0.01; 12 months vs. >30 months, *p* < 0.05; 39 kDa: *t* test: 3 months vs. 12 months, *p* < 0.05; 34 kDa: *t* test: 3 months vs. >30 months, *p* < 0.05; 12 months vs. >30 months, *p* < 0.05). (B) No change in FL STK3 is observed in the kidney. In contrast, the STK3 39-kDa fragment increases in the kidney from 23 to 28 months of age (ANOVA *p* = 0.0001, post hoc: 3 months vs. 23–28 months, *p* < 0.01; 3 months vs. >30 months, *p* < 0.001; 12 months vs. 23–28 months, *p* < 0.01; 23–28 months vs. >30 months, *p* < 0.001). (C) No significant variation in STK3 protein expression level is observed in the heart. However, an increasing linear trend is observed in the 34-kDa fragment (*p* = 0.0255). (D) No change in FL STK3 is observed in the spleen with age. However, STK3 39-kDa and 34-kDa fragment expression level increase with aging in the spleen (39 kDa: *t* test: 3 months vs. 23–28 months, *p* < 0.05; 3 months vs. >30 months, *p* < 0.01; 34 kDa: *t* test: 3 months vs. 12 months, *p* < 0.05; 3 months vs. >30 months, *p* < 0.05). n = 4 by age group. Tukey's post hoc are presented on the graphs with a continuous line and *t* tests are presented on the graphs with dotted line. **p* < 0.05; ***p* < 0.01; ****p* < 0.001. Abbreviations: ANOVA, analysis of variance; FL, full length; STK3, serine/threonine kinase 3.

with aging in the heart and the spleen (Fig. 8G and J). However, in the heart, the CASP6-cleaved subunits (p20p10) increase by 99% and CASP7 proform decreases at 12 months of age (Fig. 8J and K). A 25- to 30-fold increase is also observed in CASP8 protein expression levels in the heart (Fig. 8L). Similar to the liver, CASP6 protein expression level decreases at 12 months of age in the spleen, whereas all protein forms of CASP8, CASP7 proform, and p27 subunit demonstrate increased expression with age in the spleen (Fig. 8N–P).

An increase is observed in CASP3/7 activity in the liver with aging. No significant variation is observed in CASP6 and 8 activities (Fig. 9A). In the kidney, CASP3/7 activity increases at 23–28 months of age, while CASP8 activity shows a clear decrease at 12 months of age, however, then increases at >30 months of age (Fig. 9B). An

increase in CASP6 and 8 activities is observed in the heart with aging, whereas no significant variation is observed for CASP3/7 activity. Similarly, CASP8 activity increases with aging in the spleen (Fig. 9C and D). No significant variation is observed in CASP3/7 and 6 activities with age in the spleen (Fig. 9D).

3.5. Variation of caspases expression and activities in brain regions with aging

Decreased mRNA expression levels of all caspases analyzed are observed in the cortex with age. In the cerebellum, only a subtle increase in the mRNA expression of casp8 was observed at 23–28 months of age. Striatal mRNA expression levels of CASP6 and 8

Fig. 5. Global increase of STK3 mRNA expression levels in the brain STK3 mRNA expression increases initially then decreases with age in the cortex and the hippocampus (cortex: ANOVA $p = 0.003$, post hoc: 3 months vs. 12 months, $p < 0.01$; 12 months vs. 23—28 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.01$; hippocampus: ANOVA $p < 0.0001$, post hoc: 3 months vs. 23—28 months, $p < 0.0001$; 12 months vs. 23—28 months, $p < 0.001$; 23—28 months vs. >30 months, $p < 0.05$). An increase in striatal STK3 mRNA expression level is observed with age. In contrast, no significant variation is observed in the cerebellum (striatum: ANOVA $p < 0.0001$, post hoc: 3 months vs. 23—28 months, $p < 0.0001$; 12 months vs. 23—28 months, $p < 0.001$; 12 months vs. >30 months, $p < 0.05$). n = 5 by age group. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$. Abbreviations: ANOVA, analysis of variance; mRNA, messenger RNA; STK3, serine/threonine kinase 3.

increase with aging, and hippocampal CASP6 mRNA expression levels increase while CASP3 mRNA decreases at an age of >30 months (Fig. 10).

Striatal expression of the CASP6 zymogen decreases with age, whereas the CASP6-cleaved p20p10 form increases suggesting an increase in CASP6-prodomain cleavage upon the aging process (Fig. 11A). Furthermore, a strong increase in all protein forms of CASP8 is observed in the striatum at 23—28 months of age (proform: 85-fold, p43/41: 170-fold, p30: 28-fold, p18: 1684-fold, Fig. 11D). A global increase of caspase protein expression is also detected in the cortex with the exception of CASP7, which does not vary with age in that brain region (Fig. 11E—H). A 28- to 48-fold increase is observed in cortical CASP8 protein expression, a 30-fold increase in CASP6 p20p10, and the CASP3 zymogen increases 43% with age (Fig. 11D—H). In the cerebellum, the CASP6 zymogen and cleaved p20p10 subunits also increase by 43% and 2-fold, respectively, with aging (Fig. 11J). Furthermore, 15-fold and 61-fold increases are noted with age in the CASP8 zymogen and the cleaved p43/41 fragments, respectively (Fig. 11H). Thus, similar to the other brain regions, the protein expression level of CASP6 and 8 increase with age in the cerebellum contrary to CASP3, which protein expression decreases in this tissue (Fig. 11I, J, 11L).

Despite the increase in CASP6 and 8 mRNA and protein expression levels with aging in the cerebellum, no variation in cerebellar CASP3/7, 6, or 8 activity was observed in our samples (Fig. 12A). However, in the cortex, increasing CASP6 protein levels correlated with an increase in its activity at 23—28 months of age. Surprisingly, although the cortical protein expression of CASP8 increases, a decrease is observed in its activity (Fig. 12B).

4. Discussion

We assessed cleavage of STK3 by CASP3, 6, and 7 and the expression levels of this substrate in several tissues during aging. We also assessed CASP3, 6, 7, and 8 expression and activity in peripheral organs and brain regions in the normal murine-aging process (3—30 months of age). Overall, the pattern of mRNA and protein expression for CASP3, 6, 7, and 8, and their respective activities, vary strongly among the tissues tested and within the same organ, as observed in the different brain regions (Table 1). These results suggest a differential effect of aging on the apoptotic mechanisms and/or nonapoptotic functions of caspases. We demonstrate for the first time cleavage of STK3 by CASP7, which is often seen as redundant to CASP3 but which some studies show unique activities and substrate repertoire (Boucher et al., 2012;


Fig. 6. Global increase of STK3 protein expression levels in the brain. (A and B) STK3 protein expression level increases in the cortex and the cerebellum with age. (A) FL: ANOVA $p = 0.0006$, post hoc: 3 months versus 23—28 months, $p < 0.01$; 3 months versus >30 months, $p < 0.001$; 12 months versus >30 months, $p < 0.01$; (A) 34 kDa: ANOVA $p = 0.0002$, post hoc: 12 months versus 23—28 months, $p < 0.05$; 3 months versus 23—28 months, $p < 0.01$; 3 months versus >30 months, $p < 0.001$; 12 months versus >30 months, $p < 0.01$; (B) FL: ANOVA $p = 0.0018$, post hoc: 3 months versus 23—28 months, $p < 0.01$; 3 months versus >30 months, $p < 0.05$; 12 months versus >30 months, $p < 0.05$; 12 months versus >23—28 months, $p < 0.05$; (B) 34 kDa: t test: 3 months versus 12 months, $p < 0.01$; 12 months versus >30 months, $p < 0.05$). (C) No significant variation is observed in the FL form of STK3 in the striatum. However, the 34-kDa fragment tends to increase with age (ANOVA $p = 0.0509$, $r^2 = 0.316$ $p = 0.02$). n = 4 by age—group. Tukey's post hoc is presented on the graphs. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$. Abbreviations: ANOVA, analysis of variance; FL, full-length; STK3, serine/threonine kinase 3.

Fig. 7. Overall caspase mRNA expression levels decrease in peripheral tissues with aging. (A) Caspase-3 mRNA expression increases in the kidney and tends to decrease with aging in the heart (kidney: ANOVA $p = 0.04$, post hoc: 12 months vs. >30 months, $p < 0.05$; heart: *t* test: 12 months vs. >30 months, $p < 0.01$). No significant variation is observed in the liver and the spleen. (B) Caspase-6 mRNA expression level decreases in the liver and the heart with age (liver: ANOVA $p = 0.007$, post hoc: 3 months vs. 23–28 months, $p < 0.05$; 3 months vs. >30 months, $p < 0.05$; heart: ANOVA $p = 0.005$, post hoc: 12 months vs. >30 months, $p < 0.01$; 23–28 months vs. >30 months, $p < 0.05$). In contrast, CASP6 mRNA tends to decrease at 12 months of age and then increase at 23–28 months of age in the kidney (*t* test: 3 months vs. 23–28 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.01$). (C) Caspase-8 mRNA expression decreases in the heart and a trend decrease is observed in the liver with age (liver: 12 months vs. >30 months, $p < 0.05$; heart: ANOVA $p = 0.015$, post hoc: 3 months vs. >30 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.05$). No significant variation in CASP8 mRNA is observed in the kidney and the spleen. n = 5 by age group. Tukey's post hoc are presented on the graphs with a continuous line and *t* test are presented on the graphs with a dotted line. # No Ct is detected for the 23–28 and >30 months group for CASP6. *$p < 0.05$; **$p < 0.01$. Abbreviations: ANOVA, analysis of variance; CASP6, caspase-6; CASP8, caspase-8; mRNA, messenger RNA.

Lamkanfi et al., 2008; Slee et al., 2001). Furthermore, we show the protein expression of STK3 (FL and proteolytic fragments) globally increases throughout the organism upon the aging process.

4.1. Caspase-dependent processing of STK3

STK4, an STK3 homolog, is also a known death substrate of CASP3, 6, and 7 with cleavage resulting in the production of 36- and 40-kDa fragments, and STK3 has been previously identified as CASP3 and 6 substrates (O'Neill et al., 2005; Riechers et al., 2016). In our study, we demonstrate the cleavage of STK3 by all 3 caspases. However, whereas all caspases generate a 34-kDa STK3 fragment, CASP6 also generates a 39-kDa fragment. The apoptotic functions of the STK4 36-kDa fragment are well described in the literature (Deng et al., 2003; Kilili and Kyriakis, 2010; Kim et al., 2010; O'Neill et al., 2004; Qin et al., 2013), and some studies suggest that the 34-kDa STK3 fragment may have a similar role (Deng et al., 2003). However, to our knowledge, the existence and the production of the STK3 39-kDa fragment by a caspase have not been previously described. It is possible that these 2 fragments of STK3, as described earlier for 2 fragments of STK4, may not have the same function in vivo. Indeed, the 40-kDa fragment of STK4 produced by CASP7 cleavage has been identified to selectively phosphorylate c-Jun N-terminal kinase (JNK) and p38, while the 36-kDa fragment of STK4, produced by CASP3 cleavage, has been identified to selectively phosphorylate extracellular signal–regulated kinase (Song and Lee, 2008). Additional studies are required to provide more precision regarding the STK3 caspase-cleavage sites and the functions of the STK3 fragments produced by these cleavage events.

4.2. STK3 expression level in peripheral organs

In our studies, STK3 mRNA expression decreases in all peripheral organs except for the spleen, where an increase is observed at 23–28 months of age. In contrast to the mRNA pattern, a global increase at the protein level in virtually all forms of STK3 is observed in these organs. Interestingly, the increase in fragment expression levels is not coupled with a decrease in the intact protein expression as may be expected due to cleavage. The increase in mRNA expression (and hence of the protein) in the spleen may compensate for the increased cleavage by caspases thereby stabilizing the FL form of STK3 in this organ. In the other peripheral organs, the stable or increasing level of the intact form may be a result of an increase in the half-life of the protein with age. For instance, the interaction of STK3 with phosphorylated RASSF2, which prevents STK3 degradation, may be responsible for this stabilization of the expression (Cooper et al., 2009).

4.3. Caspases expression and processing of STK3 in the liver

The decrease in CASP6 and 8 mRNA and the decrease of CASP3 and CASP6 protein expressions in the liver with age corroborate the low cell-death rate in this organ with aging observed in other studies (Suh, 2002). The increase in the CASP8-active fragment may be more related to the nonapoptotic functions of the protease in the liver, such as cell proliferation and induction of inflammation (Ben Moshe et al., 2007). Surprisingly, we did not detect a corresponding increase in CASP8 activity in the liver. The absence of any significant variation in activity observed with aging in this organ may be a consequence of the presence of a natural inhibitor of casp8 such as c-flip or PI-9 in the protein lysates (LeBlanc, 2003). The increase observed in CASP3/7 activity at >30 months of age in the liver suggests that the increase in the 34-kDa fragment of STK3 observed may be due to CASP3 or CASP7 cleavage. It has been previously demonstrated that STK3 has predominantly antiproliferative functions within hepatocytes (Jin et al., 2009; Qin et al., 2013). Therefore, the increase in STK3 cleavage in the liver may promote these antiproliferative functions of STK3 in the aging process rather than cell death per se.

4.4. Caspases expression and processing of STK3 in the kidney

The trend increases in the 34-kDa fragment of STK3 present in the kidney may be a consequence of the increased activity of CASP3 observed in that organ. However, the increase in global

Fig. 8. Caspase protein expression levels vary with aging in peripheral organs. (A−D) The p11 caspase-3 fragment and caspase-6 proform decrease, all forms of caspase-8 increase, and no significant variation is observed with caspase-7 in the liver with aging [(A) fragment: ANOVA $p = 0.03$; (B) t test: 12 months vs. 23−28 months, $p < 0.05$; (D) proform: t-test: 3 months vs. 23−28 months $p < 0.05$; (D) p43/41: t test: 3 months vs. 12 months $p < 0.001$; 3 months vs. >30 months, $p < 0.01$; (D) p18: ANOVA $p = 0.03$]. (E) In the kidney, the caspase-3 proform increases with age (ANOVA $p = 0.014$). (F−L) A global increase in caspase-6 and caspase-8 protein levels and a trend decrease in caspase-7 protein levels are observed in the kidney and the heart with aging [(F) proform: ANOVA $p < 0.0001$; (F) p20p10: ANOVA $p = 0.0007$; (G) proform: t test: 12 months vs. >30 months, $p = 0.0502$; 23−28 months vs. >30 months, $p = 0.07$; (G) p27: t test: 12 months vs. >30 months, $p = 0.0582$; 23−28 months vs. >30 months, $p = 0.053$; (H) proform: t test: 3 months vs. >30 months, $p < 0.05$; (H) p43/41: ANOVA $p = 0.0025$; (H) p18: ANOVA $p = 0.002$; (J) p20p10: ANOVA $p = 0.0146$; (K) proform: 3 months vs. 12 months, $p < 0.05$; (L) proform: ANOVA $p = 0.0104$; (L) p43/41: ANOVA $p = 0.0037$; (L) p18: $p = 0.002$]. (I, M) No significant variation is observed in caspase-3 protein expression levels with aging in the heart and the spleen. (N and O) Caspase-6 protein expression level decreases in the spleen at 12 months of age (proform: ANOVA, $p = 0.0501$; t test: 3 months vs. 12 months, $p < 0.05$; t test: 3 months vs. >30 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.05$). [(O) p27 and caspase-7 protein levels increase at >30 months of age. (N) Proform: ANOVA, $p = 0.0516$; t test: 3 months vs. >30 months, $p < 0.05$; 23−28 months vs. >30 months, $p < 0.05$]. (P) Similar to the other peripheral organs, caspase-8 protein expression level increases with age in the spleen [(P) proform: t test: 3 months vs. 12 months $p < 0.05$; 3 months vs. 23−28 months $p < 0.05$; 3 months vs. >30 months $p < 0.05$; (P) p43/41: ANOVA $p = 0.003$; (P) p30: t test: 3 months vs. 12 months $p < 0.05$; (P) p18: t test: 3 months vs. 12 months $p < 0.01$]. n = 4 by age group. Tukey's post hoc are presented on the graphs. $*p < 0.05$; $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$. Abbreviation: ANOVA, analysis of variance.

Table 1
Summary table of the age-associated variation in STK3 and caspases expression and activity

Organ or brain region	STK3				Caspase-3					Caspase-6				Caspase-7				Caspase-8					
	RNA	FL	39 kDa	34 kDa	RNA	Pro	p30	p19/p17	Activity[a]	RNA	Pro	p20p10	Activity	Pro	p27	p20	Activity[a]	RNA	Pro	p43/41	p30	p18	Activity
Liver	↓	↓↑	↓	↑	-	-			↑	↓	↓		-	-	-		↑	↓	↑	↑		↑	-
Kidney	↓	-	↑	-	↑	↑		↓	↑	↓↑	↑	↑	-	↓	↓		↑	-	↑	↑		↑	↓↑
Heart	↓	-		-	↓	-			-	↓	-	↑	↑	↓			-	↓	↑	↑	↑	↑	↑
Spleen	↑	-	↑	↑	-	-			-	-	↓		-	-	↑	-	-	-	↑	↑	↑	↑	↑
Cortex	↑↓	↑		↑	↓	↑	-	-	-	↓	-	↑	↑	-		-	-	↓	↑	↑	↑	↑	↓
Cerebellum	↑	↑	↓↑		-	↓	↓	↓	-	-	↑	-	-	-			-	↑	↑	↑	-	-	-
Striatum	↑	-		-	-	-	-		↑	↑↓	↓	-	↑					↑	↓↑	-	↑	↑	
Hippocampus	↑↓				↓				↑				↑					-					

The arrows are representing the variation of expression observed in the organ. The "-" are representing the absence of variation of expression observed in the organ.
Key: Pro, proform; FL, full length; p20p10, CASP6 without the prodomain.
[a] An analysis of CASP3 and CASP7 activity by the same peptide.

Fig. 9. Caspase-6 activity increases in the liver and kidney and caspase-8 activity increase with aging in the kidney, heart, and spleen. (A) A trend increase is observed in CASP3/7 activity in the liver (*t* test: 3 months vs. >30 months, *p* < 0.01; 12 months vs. >30 months, *p* < 0.01). No significant variation is observed in CASP6 and 8 activities. (B) In the kidney, CASP3/7 activity increases at 23–28 months of age (*t* test: 12 months vs. 23–28 months, *p* < 0.05). Caspase-8 activity decreases at 12 months and increases at >30 months (ANOVA *p* = 0.03, post hoc: 3 months vs. 12 months, *p* < 0.05; *t* test: 12 months vs. >30 months, *p* < 0.0001). (C) An increase is observed in the heart in CASP6 and 8 activities with aging (CASP6: *t* test: 23–28 months vs. >30 months, *p* < 0.05; CASP8: *t* test: 3 months vs. 23–28 months, *p* < 0.05; 3 months vs. >30 months, *p* < 0.05). No significant variation is observed in CASP3/7 with aging in the heart. (D) Caspase-8 activity increases with aging in the spleen (*t* test: 3 months vs. 23–28 months, *p* < 0.05; 3 months vs. >30 months, *p* < 0.05). No significant variation is observed in the spleen for CASP3/7 and 6 activities with aging. n = 4 by age group. Tukey's post hoc are presented on the graphs with lines and *t* test are presented using dotted lines. **p* < 0.05; ***p* < 0.01; *****p* < 0.0001. Abbreviations: ANOVA, analysis of variance; CASP6, caspase-6; CASP8, caspase-8.

Fig. 10. Caspase-6 mRNA expression increases in the striatum and hippocampus with age. (A) Caspase-3 mRNA expression decreases in the cortex and the hippocampus with age (cortex: ANOVA $p = 0.0103$, post hoc: 3 months vs. >30 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.05$; hippocampus: t test: 3 months vs. >30 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.01$). No significant variation is observed in CASP3 mRNA expression in the cerebellum and the striatum. (B) In the cortex, caspase-6 mRNA expression decreases at 23–28 months of age (ANOVA $p = 0.04$, post hoc: 12 months vs. 23–28 months, $p < 0.05$). In contrast, caspase-6 mRNA expression increases in the striatum and the hippocampus (striatum: ANOVA $p = 0.0005$, post hoc: 3 months vs. 23–28 months, $p < 0.01$; 12 months vs. 23–28 months, $p < 0.001$; 23–28 months vs. >30 months, $p < 0.05$; hippocampus: ANOVA $p = 0.007$, post hoc: 3 months vs. >30 months, $p < 0.01$). No significant variation is observed in the cerebellum. (C) Caspase-8 mRNA expression tends to decrease at >30 months of age in the cortex. In contrast, an increase in CASP8 mRNA expression is observed in the cerebellum and the striatum (cerebellum: ANOVA $p = 0.0589$, t test: 12 months vs. >30 months, $p < 0.001$; striatum: t test: 12 months vs. >30 months, $p < 0.05$). n = 5 by age group. Tukey's post hoc are presented on the graphs with a continuous line and t test are presented on the graphs with a dotted line. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$. Abbreviations: mRNA, messenger RNA; ANOVA, analysis of variance; CASP3, caspase-3; CASP8, caspase-8.

expression of CASP6 in kidney suggests that it may also be responsible for the production of the 34-kDa fragment and suggests a role for this protease in the generation of the 39-kDa fragment, a fragment only produced by CASP6, and which is significantly increased with age in the kidney. However, no variation in activity is observed using the preferred CASP6 substrate. Therefore, it cannot be ruled out that a protease other than CASP6 cleaves STK3 to generate the 39-kDa STK3 fragments in the kidney. However, in addition to the presence of inhibitors (exogenous or endogenous) that can influence the result, the lack of specificity of the caspase-peptidic substrates used in the activity assays that are available further requires caution in interpreting the results (McStay et al., 2008). The increase in expression of STK3, and of all caspases tested (with exception of CASP7) in the kidney with aging, may reflect the increase in cell death observed previously with aging by using Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in the glomerular and corticotubular areas in the kidney (Lim et al., 2012).

4.5. Caspases expression and processing of STK3 in the heart

In the heart, a decrease in CASP3, 6, and 8 mRNA expression levels is observed with aging. Interestingly, these differences were only noted when compared to the >30 months age group. It is important to note that there are many metabolic changes observed between long-lived mice compared to their younger counterparts that could be responsible for these results (Bartke and Westbrook, 2012; Milman et al., 2014; Sherlock and Toogood, 2007) as, in general, the normal life span of C57BL/6 mice is ∼25 months. Moreover, these mice could be the result of a natural selection of a particular subgroup of individuals, which may explain this decrease in caspases mRNA at >30 months of age. In contrast to the mRNA expression levels, CASP6 and 8 protein expression and activity increases with aging, which corroborates the previously observed ∼30% loss of cardiomyocytes with age (Sheydina et al., 2011). The increase in CASP6 activity observed in the heart may be responsible for the increase in 34-kDa fragment of STK3 production observed in our results. However, the

increase in the STK3 fragment is not coupled with a decrease in the FL protein expression. As a decrease in STK3 mRNA level is observed with aging, STK3 may be a target for post-translational modifications that promote an increase in the half-life of the protein or may interact with some proteins that slow down the degradation rate of STK3, such as RASSF2 (Cooper et al., 2009).

4.6. Caspases expression and processing of STK3 in the spleen

Decreases in CASP6 protein expression and an increase in CASP7 and 8 protein expression and CASP8 activity were observed in the spleen with aging. Of note, in vivo CASP6-active fragments are very difficult to detect by Western blotting, possibly due to short protein half-life. The decrease in CASP6-proform levels may be due to the processing and activation of the caspase or a more efficient degradation as we did not detect a decrease in gene expression in the spleen. Similar to our results, an increase in the activity of CASP8 and cell death has previously been observed in old C57BL/6 mice spleenocytes (Itzhaki et al., 2003). However, they also noted an increase in CASP3 activity between 2 and 15 months in old mice, which we did not observe in our study. The difference between the ages selected (2 months of age considered in development in contrast to 3 months of age considered an adult), sex, or strain of the mice used may be responsible for this difference. A trend increase is detected in all protein forms of STK3 in the spleen with aging. As no variation is observed in CASP3 expression or CASP3/7 activity, the increase in STK3 fragment may be attributable to CASP6 and/or CASP7 as we did detect subtle processing of the zymogens in the spleen.

4.7. Caspases expression and processing of STK3 in the brain

Interestingly, the decrease in mRNA expression of STK3 and all caspases observed in the aging cortex does not reflect the variation at the protein level. All STK3 protein forms increase with age, which may be the result of a less-efficient degradation of STK3, an increase of the protein half-life, or more generally, it may be the result of the

Fig. 11. Global increase in caspases protein expression levels in the brain with the aging. (A–D) Caspase-3 does not vary with age in the striatum whereas caspase-6 tends to decrease, and caspase-7 and -8 increase with aging. [(B) proform: t test: 3 months vs. 23–28 months; (C) proform: $r^2 = 0.29$, $p = 0.04$; (D) proform: ANOVA $p = 0.007$; (D) p30: ANOVA $p = 0.007$; (D) p18: t test: 3 months vs. 12 months, $p < 0.01$]. (E–H) Caspase-3, -6, and -8 expression increases or tends to increase with age in the cortex [(E) proform: t test: 3 months vs. 12 months, $p < 0.5$; 3 months vs. >30 months, $p < 0.5$; (F) p20p10: t test: 3 months vs. 12 months, $p < 0.5$; 3 months vs. >30 months, $p < 0.5$; (H) proform: ANOVA $p = 0.009$; (H) p43/41: ANOVA $p = 0.004$; (H) p30: ANOVA $p = 0.013$; (H) p18: t test 3 months vs. 23–28 months $p < 0.05$]. (G, K) No significant variation is observed in caspase-7 protein expression level in the cortex and cerebellum. (I, J, L) Caspase-6 and -8 expression increases or tends to increase with age in the cerebellum whereas caspase-3 decreases with aging [(I) proform: t test: 3 months vs. >30 months, $p < 0.05$; 12 months vs. >30 months, $p < 0.05$; (I) 30 kDa: ANOVA $p = 0.03$; (J) proform: ANOVA $p = 0.013$; (L) proform: t test: 3 months vs. >30 months, $p < 0.05$; (L) p43/41: t test: 3 months vs. >30 months, $p < 0.05$]. n = 4 by age group. Tukey's post hoc are presented on the graphs. *$p < 0.05$; **$p < 0.01$. Abbreviation: ANOVA, analysis of variance.

decrease in proteasome activity previously observed in this brain region with aging (Baraibar and Friguet, 2012). Increase in CASP6 and decrease in CASP8 activities were observed in the cortex with aging while no variation was detected in CASP3/7 activity. Thus, the strong increase in cortical STK3 fragments may be the result of the cleavage of STK3 by CASP6. Interestingly, in contrast to peripheral tissue, no 39-kDa fragment is observed in any of the brain regions assessed, which may suggest specific peripheral functions of this particular STK3 fragment.

At the mRNA level, there is no variation observed in aging in any of the genes analyzed in the cerebellum except for CASP8 mRNA that increases. This increase in CASP8 mRNA levels is coupled with a strong increase in CASP8 protein expression. The absence of mRNA variation in CASP3 and 6 is not translated to the protein levels. A decrease in CASP3 and an increase in CASP6 protein expression are

observed with aging in the cerebellum which suggest that CASP8, and potentially CASP6, may be a key caspase in neurodegeneration in the cerebellum with aging. A previous study has observed that while there is a stable number of Purkinje cells in the cerebellum with aging, there are some sections of the cerebellum, such as the anterior lobe, in which a loss of these cells is observed with aging (Andersen et al., 2003; Zhang et al., 2010). As our analysis consisted of the entire cerebellum samples, this region-specific effect might be lost. Surprisingly, the variations at the protein level, even the strong increase in all forms of CASP8 protein levels, are not reflected in the caspase activity assay results. Our data suggest that the increase in the 34-kDa STK3 fragments observed in the cerebellum may be due to CASP6 as both the proform and the fragments increase with age in this brain region. We observe that both the FL and the STK3 34-kDa fragments increase in the cerebellum with

Fig. 12. Caspase-6 activity increases in the cortex with aging. (A) No significant variation in caspases activity is observed with aging in the cerebellum. (B) Caspase-6 increases while CASP8 activity tends to decrease in the cortex with aging (caspase-6: ANOVA $p = 0.02$, post hoc: 3 months vs. 23—28 months, $p < 0.05$; caspase-8: t test: 12 months vs. >30 months). No significant variation is observed in CASP3 activity. n = 4 by age group. Tukey's post hoc is presented on the graphs with a continuous line and t test is presented on the graphs with a dotted line. *$p < 0.05$. Abbreviations: ANOVA, analysis of variance; CASP3, caspase-3; CASP8, caspase-8.

age supporting a role for apoptosis and caspases in the cerebellum with aging.

The mRNA of CASP6 and 8 increases with age in the striatum. However, this variation is not reflected at the protein level for CASP6 which decreases with age. In contrast, all protein forms of CASP8 strongly increase with aging. Interestingly, between 23—28 months and >30 months of age, the CASP8 proform decreases by 86%, which correlates with the high amount of fragment present. Therefore, the decrease observed in the CASP8 zymogen at >30 months of age may be due to the processing and activation of CASP8. As no variation in CASP3 and a decrease in CASP6 protein expressions are observed in the striatum, the increase observed in 34-kDa STK3 fragment protein in our data may be more attributable to its processing by CASP7, which has a trend increase in expression level with aging, to a less efficient degradation of the protein or an increase of the protein half-life. Of note, no small-peptide substrate is available specifically for CASP3 or 7 (McStay et al., 2008). Therefore, we cannot confirm this hypothesis using activity assays. This increase in STK3 fragment expression correlates with the age-associated increase in apoptosis observed previously in the striatum of Wistar 2BAW rats (Ureshino et al., 2010). Of note, we did not have enough samples to assess caspase activity in the striatum.

Finally, in the hippocampus, a decrease in CASP3 mRNA expression and an increase in the mRNA of CASP6 and STK3 are observed with aging. Of note, experiments in hippocampal primary cultures demonstrate that STK4, a homolog of STK3, is phosphorylated upon oxidative stress by c-abl leading to the stabilization of the protein expression of STK4 and the STK4-FOXO-mediated cell death (Xiao et al., 2011). Moreover, CASP6 is activated in neurodegenerative diseases and its activity in the hippocampal CA1 region is sufficient to induce neuronal degeneration, inflammation, and age-related memory impairment (LeBlanc et al., 2014; Ramcharitar et al., 2013; Wang et al., 2015). Thus, the increase in mRNA expression of STK3 and CASP6, a protease that cleaves STK3, highlights a possible role for STK3 in the neurodegeneration process in Alzheimer disease and potentially other neurodegenerative

diseases. Unfortunately, we did not have enough hippocampal samples to assess protein expression of STK3 and caspases in this brain region.

5. Conclusion

Overall, our results demonstrate that the pattern of mRNA and/or protein expression of CASP3, 6, 7, and 8 and their respective activity vary strongly throughout the organism and even among the same organ (as observed in the different brain regions) suggesting differential effects of aging on the apoptotic mechanism and/or nonapoptotic functions of caspases. Moreover, STK3 expression, a newly identified substrate of CASP6 and 7, globally increases throughout the organism with the aging process. To our knowledge, this is the first time that the caspase expression and activity have been investigated as extensively throughout the entire organism during the aging process. This study provides important details regarding the pattern of expression and activity of the caspases and the caspase substrate STK3 throughout the entire organism upon a physiological stress that is the normal aging process. These results further our understanding of the effect of aging on the organism without any pathological condition.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.neurobiolaging.2016.07.003.

References

Andersen, B.B., Gundersen, H.J., Pakkenberg, B., 2003. Aging of the human cerebellum: a stereological study. J. Comp. Neurol. 466, 356–365.

Baraibar, M.A., Friguet, B., 2012. Changes of the proteasomal system during the aging process. Prog. Mol. Biol. Transl. Sci. 109, 249–275.

Bartke, A., Westbrook, R., 2012. Metabolic characteristics of long-lived mice. Front. Genet. 3, 288.

Ben Moshe, T., Barash, H., Kang, T.B., Kim, J.C., Kovalenko, A., Gross, E., Schuchmann, M., Abramovitch, R., Galun, E., Wallach, D., 2007. Role of caspase-8 in hepatocyte response to infection and injury in mice. Hepatology 45, 1014–1024.

Boucher, D., Blais, V., Denault, J.B., 2012. Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis. Proc. Natl. Acad. Sci. U. S. A. 109, 5669–5674.

Boucher, D., Duclos, C., Denault, J.B., 2014. General in vitro caspase assay procedures. Methods Mol. Biol. 1133, 3–39.

Broughton, B.R., Reutens, D.C., Sobey, C.G., 2009. Apoptotic mechanisms after cerebral ischemia. Stroke 40, e331–e339.

Chung, L., Ng, Y.C., 2006. Age-related alterations in expression of apoptosis regulatory proteins and heat shock proteins in rat skeletal muscle. Biochim. Biophys. Acta 1762, 103–109.

Cooper, W.N., Hesson, L.B., Matallanas, D., Dallol, A., von Kriegsheim, A., Ward, R., Kolch, W., Latif, F., 2009. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28, 2988–2998.

D'Amelio, M., Cavallucci, V., Cecconi, F., 2010. Neuronal caspase-3 signaling: not only cell death. Cell Death Differ. 17, 1104–1114.

Deng, Y., Pang, A., Wang, J.H., 2003. Regulation of mammalian STE20-like kinase 2 (MST2) by protein phosphorylation/dephosphorylation and proteolysis. J. Biol. Chem. 278, 11760–11767.

Graham, R.K., Ehrnhoefer, D.E., Hayden, M.R., 2011. Caspase-6 and neurodegeneration. Trends Neurosci. 34, 646–656.

Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R.L., Martin, J.F., 2011. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458–461.

Itzhaki, O., Skutelsky, E., Kaptzan, T., Sinai, J., Michowitz, M., Huszar, M., Leibovici, J., 2003. Ageing-apoptosis relation in murine spleen. Mech. Ageing Dev. 124, 999–1012.

Jin, J., Wang, G.L., Timchenko, L., Timchenko, N.A., 2009. GSK3beta and aging liver. Aging 1, 582–585.

Kilili, G.K., Kyriakis, J.M., 2010. Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J. Biol. Chem. 285, 15076–15087.

Kim, D., Shu, S., Coppola, M.D., Kaneko, S., Yuan, Z.Q., Cheng, J.Q., 2010. Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PloS one 5, e9616.

Kuranaga, E., Miura, M., 2007. Nonapoptotic functions of caspases: caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell Biol. 17, 135–144.

Lamkanfi, M., Kanneganti, T.D., Van Damme, P., Vanden Berghe, T., Vanoverberghe, I., Vandekerckhove, J., Vandenabeele, P., Gevaert, K., Nunez, G., 2008. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol. Cell Proteomics 7, 2350–2363.

LeBlanc, A.C., 2013. Caspase-6 as a novel early target in the treatment of Alzheimer's disease. Eur. J. Neurosci. 37, 2005–2018.

LeBlanc, A.C., 2003. Natural cellular inhibitors of caspases. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 215–229.

LeBlanc, A.C., Ramcharitar, J., Afonso, V., Hamel, E., Bennett, D.A., Pakavathkumar, P., Albrecht, S., 2014. Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death Differ. 21, 696–706.

Lee, K.K., Murakawa, M., Nishida, E., Tsubuki, S., Kawashima, S., Sakamaki, K., Yonehara, S., 1998. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene 16, 3029–3037.

Lee, K.K., Ohyama, T., Yajima, N., Tsubuki, S., Yonehara, S., 2001. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J. Biol. Chem. 276, 19276–19285.

Lee, S.T., Kim, M., 2006. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease. Mech. Ageing Dev. 127, 432–435.

Lessard-Beaudoin, M., Laroche, M., Demers, M.J., Grenier, G., Graham, R.K., 2015. Characterization of age-associated changes in peripheral organ and brain region weights in C57BL/6 mice. Exp. Gerontol. 63, 27–34.

Li, P., Chen, Y., Mak, K.K., Wong, C.K., Wang, C.C., Yuan, P., 2013. Functional role of Mst1/Mst2 in embryonic stem cell differentiation. PloS one 8, e79867.

Lim, J.H., Kim, E.N., Kim, M.Y., Chung, S., Shin, S.J., Kim, H.W., Yang, C.W., Kim, Y.S., Chang, Y.S., Park, C.W., Choi, B.S., 2012. Age-associated molecular changes in the kidney in aged mice. Oxid. Med. Cell. Longev. 2012, 171383.

Liu, A.M., Wong, K.F., Jiang, X., Qiao, Y., Luk, J.M., 2012a. Regulators of mammalian Hippo pathway in cancer. Biochim. Biophys. Acta 1826, 357–364.

Liu, W., Wu, J., Xiao, L., Bai, Y., Qu, A., Zheng, Z., Yuan, Z., 2012b. Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS One 7, e36562.

McStay, G.P., Salvesen, G.S., Green, D.R., 2008. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 15, 322–331.

Merksamer, P.I., Liu, Y., He, W., Hirschey, M.D., Chen, D., Verdin, E., 2013. The sirtuins, oxidative stress and aging: an emerging link. Aging (Albany NY) 5, 144–150.

Milman, S., Atzmon, G., Huffman, D.M., Wan, J., Crandall, J.P., Cohen, P., Barzilai, N., 2014. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 13, 769–771.

Oh, S., Lee, D., Kim, T., Kim, T.S., Oh, H.J., Hwang, C.Y., Kong, Y.Y., Kwon, K.S., Lim, D.S., 2009. Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Mol. Cell Biol. 29, 6309–6320.

O'Neill, E.E., Matallanas, D., Kolch, W., 2005. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res. 65, 5485–5487.

O'Neill, E., Rushworth, L., Baccarini, M., Kolch, W., 2004. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267–2270.

Patten, D.A., Germain, M., Kelly, M.A., Slack, R.S., 2010. Reactive oxygen species: stuck in the middle of neurodegeneration. J. Alzheimers Dis. 20 Suppl 2, S357–S367.

Pattison, L.R., Kotter, M.R., Fraga, D., Bonelli, R.M., 2006. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J. Neurol. 253, 1137–1142.

Qin, F., Tian, J., Zhou, D., Chen, L., 2013. Mst1 and Mst2 kinases: regulations and diseases. Cell Biosci. 3, 31.

Ramcharitar, J., Afonso, V.M., Albrecht, S., Bennett, D.A., LeBlanc, A.C., 2013. Caspase-6 activity predicts lower episodic memory ability in aged individuals. Neurobiol. Aging 34, 1815–1824.

Riechers, S.P., Butland, S., Deng, Y., Skotte, N., Ehrnhoefer, D.E., Russ, J., Laine, J., Laroche, M., Pouladi, M.A., Wanker, E., Hayden, M.R., Graham, R.K., 2016. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Hum. Mol. Genet. 25, 1600–1618.

Schwerk, C., Schulze-Osthoff, K., 2003. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem. Pharmacol. 66, 1453–1458.

Sherlock, M., Toogood, A.A., 2007. Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 10, 189–203.

Sheydina, A., Riordon, D.R., Boheler, K.R., 2011. Molecular mechanisms of cardiomyocyte aging. Clin. Sci. (Lond.) 121, 315–329.

Shimohama, S., Tanino, H., Fujimoto, S., 2001. Differential expression of rat brain caspase family proteins during development and aging. Biochem. Biophys. Res. Commun. 289, 1063–1066.

Slee, E.A., Adrain, C., Martin, S.J., 2001. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 276, 7320–7326.

Snigdha, S., Smith, E.D., Prieto, G.A., Cotman, C.W., 2012. Caspase-3 activation as a bifurcation point between plasticity and cell death. Neurosci. Bull. 28, 14–24.

Song, J.J., Lee, Y.J., 2008. Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal 20, 892–906.

Suh, Y., 2002. Cell signaling in aging and apoptosis. Mech. Ageing Dev. 123, 881–890.

Ureshino, R.P., Bertoncini, C.R., Fernandes, M.J., Abdalla, F.M., Porto, C.S., Hsu, Y.T., Lopes, G.S., Smaili, S.S., 2010. Alterations in calcium signaling and a decrease in Bcl-2 expression: possible correlation with apoptosis in aged striatum. J. Neurosci. Res. 88, 438–447.

Wang, X.J., Cao, Q., Zhang, Y., Su, X.D., 2015. Activation and regulation of caspase-6 and its role in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 55, 553–572.

Xiao, L., Chen, D., Hu, P., Wu, J., Liu, W., Zhao, Y., Cao, M., Fang, Y., Bi, W., Zheng, Z., Ren, J., Ji, G., Wang, Y., Yuan, Z., 2011. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J. Neurosci. 31, 9611–9619.

Zhang, C., Zhu, Q., Hua, T., 2010. Aging of cerebellar Purkinje cells. Cell Tissue Res. 341, 341–347.

Zhang, J.H., Zhang, Y., Herman, B., 2003. Caspases, apoptosis and aging. Ageing Res. Rev. 2, 357–366.